Real World Evidence

BBCR Company News

Recent Advance of Gene Therapy in Rare Diseases

May 13th, 2021 | Real World Evidence

Gene Therapy improved vision in patients with leber hereditary optic neuropathy (LHON) By: Dr. Maria Niu Mitochondria, powerhouses of eukaryotic cells, is a certain kind of cytoplasmic organelle and plays a critical role in energy production. Mitochondria dysfunction results in a broad spectrum of multisystem disorders. LHON is a mitochondrial neurodegenerative disease typically caused by […]

New Drug Approved in the Field of SiRNA-based Therapeutics Targeting Rare Disease

May 5th, 2021 | Real World Evidence

Lumasiran, a siRNA Therapeutic drug for primary hyperoxaluria type1(PH1) By: Dr. Maria Niu PH1 is a rare genetic disease caused by deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), resulting in overproduction of oxalate. The clinical manifestation includes kidney stones, widespread organ damage, and kidney failure. Liver transplantation is applied in PH1 patients to provide the […]

COVID-19 Pandemic and Mental Health

April 29th, 2021 | Real World Evidence

The Lancet: 34% COVID-19 survivors have neurological and psychiatric disorders By: Dr. Maria Niu Previous case reports had described the altered mental problems and psychiatric disorders in people diagnosed with COVID-19 infection. In the latest study (https://doi.org/10.1016/S2215-0366(21)00084-5) reported by The Lancet Psychiatry on April 6, 2021, the authors confirmed a high incidence of neurological and […]

The Effect of Fecal Transplant on Melanoma

April 28th, 2021 | Real World Evidence

Fecal microbiota transplantation (FMT) promotes the response of check point inhibitors (CPI) to melanoma patients By: Dr. Maria Niu Fecal microbiota transplantation (FMT) is a procedure that delivers fecal bacteria and other microbes from a healthy individual into another individual with various diseases or disorders. It has been recently tested in infection, immune conditions, and […]

Drug Development for Rare Duchenne Muscular Dystrophy (DMD)

April 20th, 2021 | Real World Evidence

Progress and limitation of therapeutic approaches targeting DMD By: Dr. Maria Niu Duchenne muscular dystrophy (DMD) is an X—a chromosome-linked recessive disorder caused by mutations in the gene coding muscle cytoskeletal protein dystrophin. Because of the X-linked inheritance, nearly 1 in 3,500 males are affected worldwide, while females occasionally develop symptoms. There is no curative […]

Mutants: the challenges of COVID 19 Vaccine

April 13th, 2021 | Real World Evidence

True or false: Virus variants weaken the effectiveness of COVID 19 Vaccine Coronavirus vaccines have significantly reduced the infectiousness of COVID 19 cases and showed significant protective efficacy against COVID 19. However, the recent reported COVID19 variants B.1.1.7 in the UK and B.1.351 in South Africa are of concern because of their more accessible and […]

Cell and gene advanced therapy in the Battle for Lysosomal Storage Disease

April 8th, 2021 | Real World Evidence

Emerging cell and gene therapy may offer sustained long-term correction for LSD patients Dr. Maria Niu Lysosomal storage diseases (LSDs) are rare inherited metabolic diseases and characterized by the accumulation of substrates in excess in various organs’ cells due to lysosomes’ defective functioning. The combined incidence of LSDs is between 1 in 5000 to 1 […]

BBCR offers innovative approaches to de-risk your product development during Early Clinical Development

April 2nd, 2021 | Real World Evidence

Depending on your project goals, our consultants work with you to design cost-effective early clinical studies that hold potential for reducing Phase III failures. Our services include: POM & POC Translational Research Clinical Plan & Study Design Phase 1 & 2 Protocol Development Medical Monitors Study Management  

BBCR has experience in biologics for rare diseases and can assist with the development of a targeted strategy to meet your study needs.

March 24th, 2021 | Real World Evidence

Biologic treatments show promise in providing clinical solutions to a variety of diseases including rare cancers and precision medicine. Services include: Indications analysis and prioritization Strategic drug assessment Clinical study design and protocol Biomarker strategy Early Clinical Development FDA meeting and submission Pre-ND integrated development plan CRO and project management Study remediation and rescue   […]

Our Strategic Clinical Innovation Organization or SCIO method enables our clients to save time, create cost efficiencies, and reduce risk on the path to achieving optimal product market positioning. Reach out to BBCR today to learn more.

March 17th, 2021 | Real World Evidence

Our Strategic Clinical Innovation Organization (“SCIO”) method enables our clients to save time, create cost efficiencies, and reduce risk on the path to achieving optimal product market positioning. The Strategic Clinical Innovation Organization (SCIO) concept developed by BBCR was designed specifically to help pharmaceutical innovators address the concerns and maneuver around evolving challenges.  SCIO allows […]

Pin It on Pinterest